Zacks Research Lifts Earnings Estimates for Elevance Health

Elevance Health, Inc. (NYSE:ELV) – Analysts at Zacks Research raised their FY2026 EPS estimates for Elevance Health in a research report issued on Tuesday, November 3rd. Zacks Research analyst Team now expects that the company will post earnings of $29.02 per share for the year, up from their previous forecast of $27.06. The consensus estimate for Elevance Health’s current full-year earnings is $29.18 per share. Zacks Research also issued estimates for Elevance Health’s Q4 2026 earnings at $2.00 EPS, Q1 2027 earnings at $11.73 EPS, Q3 2027 earnings at $6.01 EPS, Q1 2028 earnings at $12.61 EPS and Q3 2028 earnings at $7.09 EPS.

A number of other equities analysts also recently issued reports on the company. Wells Fargo & Company increased their target price on Elevance Health from $473.00 to $492.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 27th. Barclays raised their price target on Elevance Health from $469.00 to $472.00 and gave the company an “overweight” rating in a report on Thursday, October 22nd. Guggenheim lifted their price target on Elevance Health from $460.00 to $485.00 and gave the company a “buy” rating in a research note on Thursday, October 22nd. UBS Group upped their price objective on Elevance Health from $460.00 to $523.00 and gave the stock a “buy” rating in a report on Thursday, October 22nd. Finally, Robert W. Baird increased their price objective on Elevance Health from $393.00 to $406.00 and gave the stock a “neutral” rating in a research report on Thursday, October 22nd. Fifteen investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, Elevance Health presently has a consensus rating of “Moderate Buy” and an average price target of $456.48.

Elevance Health Price Performance

Shares of ELV opened at $434.44 on Thursday. Elevance Health has a twelve month low of $274.84 and a twelve month high of $450.69. The stock’s 50 day moving average is $411.80 and its two-hundred day moving average is $373.00. The firm has a market capitalization of $93.86 billion, a PE ratio of 18.53, a P/E/G ratio of 1.97 and a beta of 0.63. The company has a current ratio of 1.47, a quick ratio of 1.47 and a debt-to-equity ratio of 0.68.

Elevance Health (NYSE:ELV) last posted its quarterly earnings results on Wednesday, October 21st. The company reported $6.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.71 by $2.28. The firm had revenue of $50.44 billion during the quarter, compared to analysts’ expectations of $49.28 billion. Elevance Health had a net margin of 2.55% and a return on equity of 14.97%. The firm’s revenue for the quarter was up .7% on a year-over-year basis. During the same period in the prior year, the company posted $6.03 earnings per share.

Elevance Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, December 18th. Shareholders of record on Friday, December 4th will be given a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a yield of 1.6%. The ex-dividend date is Friday, December 4th. Elevance Health’s dividend payout ratio is presently 29.34%.

Insider Transactions at Elevance Health

In other Elevance Health news, CFO Mark Kaye sold 10,584 shares of the stock in a transaction dated Thursday, October 22nd. The shares were sold at an average price of $440.13, for a total value of $4,658,335.92. Following the completion of the transaction, the chief financial officer directly owned 19,919 shares of the company’s stock, valued at approximately $8,766,949.47. This trade represents a 34.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.34% of the company’s stock.

Institutional Investors Weigh In On Elevance Health

Several institutional investors have recently modified their holdings of the company. Keybank National Association OH boosted its position in Elevance Health by 1.0% during the third quarter. Keybank National Association OH now owns 9,146 shares of the company’s stock worth $3,556,000 after purchasing an additional 95 shares in the last quarter. 71 West Capital Partners increased its position in shares of Elevance Health by 9.9% in the third quarter. 71 West Capital Partners now owns 1,029 shares of the company’s stock valued at $400,000 after buying an additional 93 shares in the last quarter. Gryphon Financial Partners LLC increased its position in shares of Elevance Health by 7.2% in the third quarter. Gryphon Financial Partners LLC now owns 1,200 shares of the company’s stock valued at $466,000 after buying an additional 81 shares in the last quarter. Vestor Capital LLC raised its stake in shares of Elevance Health by 317.2% during the 3rd quarter. Vestor Capital LLC now owns 997 shares of the company’s stock worth $388,000 after buying an additional 758 shares during the last quarter. Finally, AlphaCore Capital LLC raised its stake in shares of Elevance Health by 45.8% during the 3rd quarter. AlphaCore Capital LLC now owns 6,575 shares of the company’s stock worth $2,557,000 after buying an additional 2,066 shares during the last quarter. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Key Headlines Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Zacks raised its FY2026, FY2027 and FY2028 EPS estimates to $29.02, $29.97 and $33.39, respectively. It also lifted forecasts for Q1 2027, Q2 2027, Q1 2028 and Q2 2028, signaling improved expectations in several periods. MarketBeat Elevance Health
• Positive Sentiment: A market report said Elevance shares rose alongside Cigna as CVS fell following its proposed corporate split, potentially reflecting relative investor preference for Elevance. CVS Tumbles on Plan to Split
• Negative Sentiment: The revisions were not uniformly positive: Zacks cut its EPS estimates for Q4 2026, Q3 2027, Q4 2027 and Q3 2028. These reductions temper the signal from its higher full-year forecasts and suggest uneven quarterly expectations. MarketBeat Elevance Health

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a diversified health benefits company that provides health insurance and related services in the United States. Its offerings serve employers, individuals and families, as well as members of government-sponsored programs, including Medicare and Medicaid. The company provides medical, pharmacy, behavioral health and other benefits through a range of health plans and specialty products.

Elevance Health operates its health benefits businesses through a portfolio that includes Blue Cross and Blue Shield-affiliated plans and other insurance offerings.